CINCINNATI--(BUSINESS WIRE)--Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaqTM Blood-PCR Kit, developed for fast, highly-specific PCR direct from whole blood samples.
Based on the proven MyTaqTM HS DNA polymerase, in combination with a novel, red-colored, buffer system; the new Bioline MyTaqTM Blood-PCR Kit overcomes the PCR inhibitors typically present in whole blood samples in a rapid, easy-to-use protocol.
By using the MyTaqTM Blood-PCR Kit researchers can expect faster protocols, higher yields and direct gel loading compared to traditional methods that require complex DNA purification steps and final sample processing.
Marco Calzavara, President of Bioline commented, "With MyTaqTM Blood-PCR Kit, researchers can now quickly and easily achieve the purity and yield necessary for high-performance PCR direct from mammalian blood samples. This makes MyTaqTM Blood-PCR Kit the perfect complement to our widely used PCR reagents.”
Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We are delighted to release the MyTaqTM Blood-PCR Kit which simplifies the process of PCR extractions from whole blood samples. We are committed to our life science customers and to bringing innovation and quality products; such as the MyTaqTM Blood-PCR Kits to the research laboratory, clinical diagnostic laboratories, and biotechnology companies.”
The MyTaqTM Blood-PCR Kit has been validated with whole blood samples from a number of mammalian species types and is particularly suitable for multiplexing, GC rich and longer amplicon applications. Furthermore, the speed, specificity and simplicity of the MyTaqTM Blood-PCR Kit makes it ideal for and high-throughput genotyping assays.
For complete information, please visit www.bioline.com/MyTaq.
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
For more information about Bioline, please visit www.bioline.com
For more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
For more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com
Richard L. Eberly, firstname.lastname@example.org